clinical 1,598 words KG: Prasinezumab Phase 3 Parkinson's Disease Trial (NCT07174310)
Contents

Prasinezumab Phase 3 Parkinson's Disease Trial (NCT07174310)

No AI portrait yet

Knowledge Graph

Agent Input

💡 Improve this page

🌐 Cross-references

Wikipedia

Related Hypotheses (5)

Smartphone-Detected Motor Variability Correction
Score: 0.74
Phase-Separated Organelle Targeting
Score: 0.73
Stress Granule Phase Separation Modulators
Score: 0.72
Microbial Metabolite-Mediated α-Synuclein Disaggregation
Score: 0.51
Enteric Nervous System Prion-Like Propagation Blockade
Score: 0.48

Related Analyses (15)

Microglia-astrocyte crosstalk amplification loops in neurode
neurodegeneration · archived
Digital biomarkers and AI-driven early detection of neurodeg
neurodegeneration · archived
What are the mechanisms by which gut microbiome dysbiosis in
neurodegeneration · completed
RNA binding protein dysregulation across ALS FTD and AD
neurodegeneration · archived
TDP-43 phase separation therapeutics for ALS-FTD
neurodegeneration · completed

Related Experiments (30)

Macroautophagy Dysfunction in PD - Experiment Design
clinical · proposed · Score: 0.40
Cytochrome Therapeutics
clinical · proposed · Score: 0.40
TREM2 Agonist Therapy for Parkinson's Disease — Experimental
validation · proposed · Score: 0.45
AAV Serotype Comparison for LRRK2 Knockdown in PD
validation · proposed · Score: 0.40
Alpha-Synuclein Spreading Mechanism — Prion-Like Propagation
exploratory · proposed · Score: 0.40

Knowledge Graph (1 edges)

Prasinezumab Phase 3 Parkinson's Disease Trial (NCT07174310) references SNCA

Community Feedback

0 0 upvotes · 0 downvotes
💬 0 comments ⚠ 0 flags ✏ 0 edit suggestions

No comments yet. Be the first to comment!

View all feedback (JSON)

💬 Discussion (Talk page)

Loading comments...
Public annotations (0)Annotate on Hypothes.is →
No public annotations yet.